Seattle Genetics (SGEN) Gets a Hold Rating from Cowen & Co.
In a report released today, Boris Peaker from Cowen & Co. maintained a Hold rating on Seattle Genetics (), with a price target of $80.00. The company's shares closed last Monday at $101.80, close to its 52-week high of $101.95.
According to TipRanks.com, Peaker is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -2.8% and a 38.0% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics Inc, Stemline Therapeutics Inc, and Mersana Therapeutics Inc.
Seattle Genetics has an analyst consensus of Moderate Buy, with a price target consensus of $90.80.See today's analyst top recommended stocks >>
Based on Seattle Genetics' latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $79.24 million. In comparison, last year the company had a GAAP net loss of $67.45 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Seattle Genetics, Inc. is a biotechnology company, which engages in the development and commercialization of antibody-based therapies for the treatment of cancer. Its product Adcetris is an antibody-drug for the treatment of lymphoma. The firm is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers.
The worst Dow Jones performers so far this year, through Sept. 30, include several health care and industrial stocks. Among them, Walgreens Boots Alliance ( WBA), 3M ( MMM), Pfizer ( PFE), UnitedHealth
At a cancer-medicine conference in Barcelona this week, researchers showed off treatments that will expand patients' choices and heighten competition among biotech companies. There was new evidence for rival immunotherapies from Merck (ticker:
Boot Barn stock, today's feature in IBD 50 Stocks To Watch, proved extremely volatile Aug. 1 after reporting earnings. But a Composite Rating of 96 makes it one of many stocks to watch in the
Seattle Genetics ( SGEN - Get Report) was rising Monday after analysts at Stifel raised their price target on the stock to $95 from $69 on positive results from its bladder cancer treatment candidate.
The five-day European Society of Medical Oncology, or ESMO, Congress 2019 is set to conclude Tuesday in Barcelona, Spain. Touted as a congress where the exchange of translational cancer science of excellence takes place,
What happened Shares of ( Seattle Genetics NASDAQ:SGEN) are up 12% at 12:05 p.m. EDT after the biotech presented a pair of positive clinical trial results at the 2019 European Society for Medical Oncology (ESMO) Congress. So
Seattle Genetics ( SGEN +10.2%) breaks out to an all-time high after the company and partner Astellas Pharma ( OTCPK:ALPMY) presented "encouraging" initial results for a bladder cancer treatment. SGEN says 45 patients were evaluated for
Dive Brief: Seattle Genetics is known best for Adcetris, a cancer drug and its only approved product. Results from two studies presented over the weekend suggest the Bothell, Washington-based biotech's future could be more diversified. In one,
More News in Genetics
Credit: CC0 Public Domain A team from the Broad Institute of MIT and Harvard has developed a new CRISPR genome-editing approach by combining two of the most important proteins in molecular biology-CRISPR-Cas9
Credit: CC0 Public Domain Researchers have found a link between 48 common genetic variations and the size of the brainstem and other subcortical structures deep within the brain. These structures control a
For all the ease with which the wildly popular CRISPR-Cas9 gene-editing tool alters genomes, it's still somewhat clunky and prone to errors and unintended effects. Now, a recently developed alternative offers greater control over genome
Scientists have created a new gene-editing technique that overcomes some of the biggest drawbacks of the popular gene-editing tool CRISPR. Gene editing's core goal is to quickly and accurately edit genetic code,
Greenville woman undergoes preventative surgeries in light of genetic testing October was established as breast cancer awareness month in 1985. Research, early detection and treatment have progressed by leaps and bounds in 34 years. Among those
Scientists have raised fresh hopes for treating people with genetic disorders by inventing a powerful new molecular tool that, in principle, can correct the vast majority of mutations that cause human genetic diseases. The procedure, named